Exelixis (NASDAQ:EXEL) is down 5.95% to $32.10 as of 11:04 AM ET Friday, following a downgrade from Oppenheimer, which cut its rating to Perform from Outperform due to concerns over drug differentiation. The firm pointed to uncertainty between Exelixis' cancer therapies, zanzalintinib and cabozantinib, after reviewing an abstract from the STELLAR-001 study presented at the ASCO GI medical meeting.
While Oppenheimer noted that the data may help de-risk the Phase 3 STELLAR-303 trial in metastatic colorectal cancer (mCRC), analysts do not yet see clear differentiation for zanzalintinib. With this lack of clarity, Oppenheimer is taking a cautious stance, choosing to stay on the sidelines until more data emerges. As a result, the firm lowered its price target from $41 to $33, reflecting a more neutral outlook on the stock.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。